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Abstract: 
 
Background and aims: Glycemic control among patients with diabetes mellitus is associated with a marked 
reduction of both macrovascular and microvascular complications; however, glycemic control remains an 
elusive goal worldwide. The aim of this study was to determine factors associated with glycemic control among 
patients attending a tertiary clinic in Botswana as limited information to date. Methods: Cross-sectional study in 
a tertiary clinic in Gaborone, Botswana. Patients were recruited between 21st July 2015 and 21st September 
2015. The majority of the randomly recruited patients (368/380 - 96.8%) had documentation of glycemic control 
(HbA1c) within three months of study recruitment and were subsequently included in the analysis. Glycemic 
control was categorized as desirable, suboptimal and poor if HbA1c was < 7%, 7-9% and > 9% respectively.  
Data was analyzed using SPSS for descriptive statistics including both bivariate and multinomial logistic 
regression. Ap-value < 0.05 was considered statistically significant. Results: The analyzed study population 
consisted of 258/368 (70.1%) females with a mean age (SD) of 56.7± 13.6 years. Means (SDs) for diabetes 
duration and glycated haemoglobin were 7.2± 7.1 years and 7.97± 2.02% respectively. Of the 368 patients,  
136 (36.95%) and 132/368 (35.86%) had desirableand suboptimal  glycemic control respectively.  Older age, 
attending the clinic for more or equal to 3 years and not being on insulin were associated with both desirable 
and suboptimal glycemic control whereas duration of diabetes between 5-10 years was associated with poor 
glycemic control.  Conclusions: The majority of patients had poor glycemic control. Older age and not being on 
insulin were associated with better glycemic control. The fact that patients on insulin had poor glycemic control 
calls for more research to determine timing of insulin initiations and dosing schedule factors as these will help 
toimprove overall glycaemic control in Botswana and elsewhere.    
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1. Introduction 
 
Diabetes mellitus (DM) is a global pandemic, contributing appreciably to worldwide morbidity and mortality [1, 
2]. This is particularly an issue in Africa where in 2010, 12.1 million people were estimated to be living with 
diabetes, and this is projected to increase to 23.9 million by 2030 [3]. In for instance in South Africa, 61% of the 
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population are currently overweight, obese or severely obese [4], increasing future prevalence rates for DM 
unless addressed. According to 2015 International Diabetes Federation (IDF) data, 1 in 25 adults in Botswana 
currently have DM, which is growing. Overall, approximately 52,000 adults in Botswana currently have DM, with 
over 60% currently remaining undiagnosed. The overall prevalence of DM and impaired glucose tolerance (IGT) 
in Botswana in 2015 was estimated at 5.6% and 7.1% respectively [5]. 
 
Previous studies, including randomized controlled trials, have consistently shown that tight glucose control is 
associated with a reduction of both microvascular and macrovascular complications [1, 6-9]. In addition, 
improving patients’ quality-of-life [10, 11]. Despite this evidence, a high proportion of DM patients remain poorly 
controlled across countries [3,4,11-15]; consequently, patients are at risk of complications of DM. The 
challenges of failing to attain optimal glycemic control in clinical practice are complex [16]; including both patient 
and health-care provider related factors. Patient related factors include, but not limited to, medication 
adherence, fear of hypoglycemia, disease process and patients’ attitudes; health-care factors include the 
number of hospital visits, types and number of antidiabetic medications being prescribed and health-provider 
attitudes [16, 17]. Previous studies have shown that several factors influence glycemic control. These include 
age, gender, race/ethnicity, education, marital status, body mass index, duration of diabetes, smoking, type and 
number of medications used, dietary habits and psychological aspects [16, 18, 19]. However, published studies 
have shown inconsistency, and in almost 50% of occasions the reason for poor glycemic control cannot be 
explained [20]. 
 
This study was conducted to determine sociodemographic and clinical factors associated with glycemic control 
among DM patients attending a tertiary clinic in Botswana. Limited information is currently available regarding 
possible factors that help determine glycemic control among patients with DM in Botswana. This is important as 
the prevalence of diabetes is growing across sub-Sahara Africa including Botswana [3,4,21, 22]. We are aware 
that factors such as genetics, dietary patterns, and cultural backgrounds, may play a role in glycemic control. 
However, it is important to have local understanding to guide future studies and policies to improve glycemic 
control in Botswana, and ultimately reduce the extent of complications arising from DM. These findings may 
also be of interest to other sub-Saharan African countries as they try to improve the management of their 
patients with diabetes. 
 
2. Materials and Methods 
 
2.1 Study design, population and data collection 
This was a cross-sectional study conducted among patients with Type 2 DM attending a tertiary clinic at 
Princess Marina Hospital (PMH) in Gaborone, Botswana. PMH is the leading tertiary public hospital in 
Botswana offering services to over 3000 diabetic patients, a number of whom will also have HIV and other co-
morbidities, which may impact on medication adherence if pill counts are appreciably increased [22]. The data 
used for analysis in this study emanates from two primary studies, which have previously been published. Full 
details of how patients were selected for this study, along with their sociodemographic and clinical variables, 
can be found elsewhere [11, 22].  
 
Briefly, the clinic in this tertiary hospital provides services for patients with DM including physician consultations, 
health education, and eye and foot screening as well as issuing medicines, which are provided free-of-charge. 
On average 1,800 to 2,000 diabetic patients visit the clinic monthly with 1,400 of these visitations including 
physician consultations. Previously, we showed that glycemic control was not associated with adherence to 
antidiabetic medication overall, except for a subgroup of HIV-positive patents. There was better adherence to 
antidiabetic medicines among HIV-positive patients compared with HIV-negative patients and those with 
unknown serostatus [22]. Consequently, we undertook this study to examine further the determinants of 
glycemic control among our study participants. For the purpose of this study, 368/380 (96.8%) patients had 
recent results (within 3 months) for glycosylated haemoglobin (HbA1c); hence they were included in this 
analysis. Glycemic control (HbA1c) was categorized into three categories as follows: desirable (<7%), 
suboptimal (7-9%) and poor (≥9%) [23]  Body mass index (BMI) was calculated as a ratio of weight in kg 
divided by height in m2 and categorized as underweight (< 18.5), normal weight (18.5-24.9), overweight (25-
29.9) and obese (≥30). BMI categorization was done according to World Health Organization (WHO) [24]. 
Results of patients’ haemoglobin (Hb) were also extracted from the hospital Intergrated Patient Management 
System (IPMS) and categories of anaemia were made according to WHO as follows; Hb< 13g/dl for men and 
Hb< 12g/dl for women. Sub-categories of anemia were mild (11-11.9g/dl for women and 11-12.9 for men);  
moderate (8-10.9g/dl) and severe (< 8g/dl) [25]. 
 
At our clinic,during their first visit patients are screened for autoimmune and pancreatic antibodies. Patients 
categorized as type 1  DM had either of the two types of antibodies detected. Whilst the majority of patients’ 
antibodies results could not be traced for verification, we relied largerly on a diagnosis of DM as type 1 or 2 
based on the diagnosis documented in the patients’ folders. 
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Ethical clearance was obtained from Institutional Review Boards of Princess Marina Hospital, University of 
Botswana and the Ministry of Health, Botswana. 
 
2.2 Statistical analysis 
Descriptive statistics were used to summarize patients’ sociodemographic and clinical characteristics. Statistical 
analysis was carried out using Statistical Package for Social Sciences (SPSS, version 22).  Chi-square test was 
used to assess statistical significance of the difference in the percentages of good glycemic control according to 
independent categorical and continuous variables. One-way analysis of variance (ANOVA) was applied for 
comparisons of mean serum creatinine between three glycemic categories goups. Multinomial logistic 
regression models were performed to determine factors associated with glycemic control. All the independent 
variables studied were analyzed using both bivariate and multinomial logistic regression so as to ensure the 
impact of missing data, unbalanced sample size and large intragroup variation is countered as explained by 
Simpson’s paradox [26]. A 95% confidence interval and p value less than 0.05 was considered statistically 
significant. 
 
3. Results 
 
3.1 Sociodemographic and clinical characteristics 
 Out of the 368 patients, 258 (70.1%) were female; mean age of study population was (SD) of 56.7± 13.6 years 
with 71.4% aged more or equal to 51 years. Means (SDs) for diabetes duration and glycated haemoglobin were 
7.2± 7.1 years and 7.97± 2.02% respectively. Approximately 40% of patients were illiterate with either no formal 
education or not completed primary school.  The majority of the study population who had complete data for 
body mass index were either overweight or obese, consisting of 256/326 (78.5%) patients. Moderate anemia 
was found in 29/368 (7.9%) of the study participants (Table 1). Other sociodemographic and clinical 
characteristics are summarized in Table 1. 
 
Insert Table 1 
 
3.2 Determinants of Glycemic control 
Of the 368 patients, only 136 (36.9%) had desirable glycemic control. Univariate analysis showed that older age 
groups  were associated with desirable glycemic control in that 35.8% and 51.5% of patients aged 51-65 and ≥ 
66 years respectively had desirable glycemic control compared to 16.7% and 28% of those aged 21-35 and 36-
50 years. In addition,42.5% of patients with a duration of diabetes < 5 years had desirable glycemic control 
compared to 31.2% of those with a duration of diabetes > 10 years . Bivariate analysis revealed that older age, 
duration of diabetes of 5-10 years, duration of attending the clinic of ≥ 3 years and monotherapy with oral 
hypoglycemic agents  were associated with better glycemic control (Table 2). Other sociodemographic and 
clinical variables did not have statistical significance (Table 2).  
Insert Table 2 
 
3.3 Multinomial regression analysis of factors associated with good glycemic control 
In mind of the Simpson effect whereby some variables with either missing data in our study such as unknown 
HIV positive patients might have resulted into wrong bivariate analysis findings, we decided to run all the 
studied variables into a multinomial analysis model regardless of their significance in bivariate analysis.The type 
of diabetes caused some unexpected singularities in the hessian matrix which could give invalid estimates, 
hence it was removed from the final model. Older age, attending the clinic for more or equal to 3 years and not 
being on insulin were associated with both desirable and suboptimal glycemic control whereas the duration of 
diabetes between 5-10 years was associated with poor glycemic control.  Of note is the fact that glycemic 
control was not associated with the degree of anaemia.(Table 3). 
 
Insert Table 3 
 
3.4 Association between serum creatinine and glycemic control 
There was no significant difference in renal function using mean serum creatine between the three categories of 
glycemic control (p-value = 0.645) (Table 4) 
 
Insert Table 4 
 
4. Discussion 
 
This study revealed that majority of our patients (60.1%) had poor glycemic control. This high proportion of 
patients with poor glycemic control is similar though to the findings from other previous studies [27-31]. 
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It is paramount to point out that the use of glycosylated haemoglobin (HbA1c) to assess diabetes control should 
be interpreted with caution. HbA1c is recognized as a relaiable marker of excess glycation and it is an 
intergrator of both fasting and post-prandial glycemic disorders [32, 33]. On the other hand, results of HbA1c 
can be affected by several different factors including but not limited to genetic, physiological, haematological 
and illness-related factors such as haemolyticanaemia, hemoglobinopathies, acute and chronic blood loss, 
chronic malaria, pregnancy and serum creatinine [34-36]. Hence, variations in measurents of HbA1c are 
expected especially in different ethinic and racial populations [37, 38], calling upon for the need for validation. 
Care of patients with DM in Botswana  has adopted Society of Endocrinolofy and Metabolism of South Africa 
(SEMDSA) guidelines [39] which recommends HbA1c for glycemic control. On the other hand, a recent study in 
Botswana looking at diagnostic accuracy found a modest relationship between HbA1c and fasting blood 
glucose [40]. 
 
Despite the lack of local research on some conditions that could affect HbA1c levels in our settings, clinical 
evidence indicates that malaria is non-endemic in the  southern part of Botswana where this study was 
conducted; furthermore haemogloninapthies such as sickle cell disease are very rare.  
 
The degree of anaemia and serum creatininine have been found to affect measurements of glycosylated 
haemoglobin in contrasting ways in previous studies [36, 41-43]. However, when we analyzed these two 
variables we did not find  any association with HbA1c. 
 
It has been consistently shown that a longer the duration of diabetes is associated with progressive impairment 
of insulin secretion [8] as well as poorer adherence to antidiabetic medications; hence poor glycemic control 
[18, 19, 31, 44-47]. However, our study showed contrasting findings whereby the duration of diabetes of 5-10 
years was  associated with both desirable and suboptimal glycemic control compared to duration of diabetes of 
> 10 years. One possible explanation is that majority of our patients were diagnosed late (less than 5 years 
prior to the interval date) and they already had presented with complications [22]. We will be following this up in 
future research projects. 
 
Previous studies have shown that old age is associated with better glycemic control [48-52]; probably because 
old people tend to have more complications with their symptoms [52] which could enhance adherence to 
antidiabetic medications. Our study also found consistent findings whereby older people had better glycemic 
control.  
 
The increased number of medicines a patient is currently taking has also been associated with poor glycemic 
control. This may be a reflection of the efforts of physicians to increase the type and dosage of medicines used 
to counter poor glycemic control and associated complications [27, 53, 54], with pill burden known to adversely 
affect adherence [22, 53, 55]. However, our study revealed no significant association between the number of 
oral hypoglycemic agents in use  and glycemic control. The reasons for this might be multifactorial. We 
paroxically found that patients whose treatment regimen did not include insulin regimen had a significant 
chance of having either desirable or suboptimal glycemic control. The possible explanation for this are factors 
such as the timing of initiation of insulin and insulin regimen schedules. This phenomenon has also been 
reported elsewhere [56, 57 ], and we will again be looking at this further in future research projects. 
 
The combination of other factors such asa reluctance among physicians to initiate insulin early and wait until the 
disease has worsened, or a combination of other factors including a lack of physical exercise and diet 
modifications, may have contributed to overall poor glycemic control in our study particpants. Having said this, 
the contribution of physical exercise and diet to glycemic control in our patient population was not evaluated, 
which will need further exploration in the future.  
 
Our study also revealed no significant association between glycemic control and other variables including 
gender, level of education, marital status, and blood pressure control. This is similar though to the findings from 
previously published studies [58, 59]. 
 
Higher body mass index (BMI) has been shown to be a predictor of poor glycemic control in previous studies 
[51, 60, 61]. However, this was in contrast to our study where BMI was not associated with glycemic control. A 
possible explanation for this is that our sample population consisted of an appreciably number of patients with 
higher BMIs, with over 75% of patients already being either overweight or obese. This will again be looked at 
further given the extent of patients overweight or obese in our study population. 
 
Our previous study showed that glycemic control was not associated with adherence to antidiabetic medication 
[22]. This underpins the fact that glycemic control may partly be affected by other self-management behaviors 
such as self-monitoring of glucose and self-care activities such as number of clinic visits which, as mentioned, 
we did not evaluateOur clinic also provide a range of other services including foot care, eye examination, and 
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dietary couseling. The extent of adherence to such activities was not studied and they will also be the subject of 
future research.  
 
According to Hartz et al, patients’ understanding of diabetes and adherence to recommended behaviors was 
associated with better glycemic control compared to physiological factors [54]. However, this association was 
not studied in our population, and needs to be addressed to guide future policies alongside looking more closely 
at patients with  diabetes mellitus  This will also be studied in future research projects in this and others clinics 
across Botswana to provide additional guidance of possible measures to improve glycemic control in the future 
given current concerns. 
 
4.1 Study limitations 
 
It is imperative that our findings are interpreted on the background of several limitations. Firstly, this is a cross-
sectional study design and does not explain causality. Secondly, we did not study self-management behaviors 
and we know psychosocial variables impact on glycemic control, which have been found to affect glycemic 
control in previous studies.Lastly, we did not collect data on fasting and post-prandial to compare with HbA1c 
levels. Despite these limitations, we believe our study findings are robust and offer insight for future targeted 
interventional studies in diabetes patients  by providing epidemiological data and helping prioritize  
management decisions in situations where there are limited resources. 
 
5. Conclusions 
 
The majority of patients in our clinic in Botswana had poor glycemic control, similar to most published studies. 
Older age and not being on insulin were associated with better glycemic control. The fact that patients on 
insulin had poor glcycemic control calls for more research to determine the timing of insulin initiations and 
dosing schedule factors as these will help to better improve overall glycaemic control in patients with diabetes in 
Botswana and elsewhere.    
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Tables 
 
 
Table 1: Sociodemographic and clinical characteristics of study participants 
 
 
Variables 
Glycemic control  
Total Desirable 
(<7%) 
Suboptimal 
(7-9%) 
Poor 
(>9%) 
Gender 
Male 
Female 
 
33 (30.0%) 
103 (39.9%) 
 
39 (35.5%) 
93 (36.0%) 
 
38 (34.5%) 
62 (24.0%) 
 
110 
258 
Age in years 
21-35 
36-50 
51-65 
≥66 
 
5 (16.7%) 
21 (28.0%) 
58 (35.8%) 
52 (51.5%) 
 
5 (16.7%) 
28 (37.3%) 
67 (41.4%) 
32 (31.7%) 
 
20 (66.7%) 
26 (34.7%) 
37 (22.8%) 
49 (48.5%) 
 
30 
75 
162 
101 
Highest level of education 
No formal education 
Less than primary school 
Primary school completed 
Secondary school completed 
College/University completed 
Postgraduate degree 
 
30 (43.5%) 
31(40.3%) 
36 (35.6%) 
23 (31.1%) 
12 (29.3%) 
4 (66.7%) 
 
23 (33.3%) 
24 (31.2%) 
44 (43.6%) 
27 (36.5%) 
13 (31.7%) 
1 (16.7%) 
 
16 (23.2%) 
22 (28.6%) 
21 (20.8%) 
24 (32.4%) 
16 (39.0%) 
1 (16.7%) 
 
69 
77 
101 
74 
41 
6 
Marital status 
Never married 
Currently married 
Separated 
Divorced 
Widowed 
Cohabiting 
 
32 (32.7%) 
62 (40.8%) 
0 (0%) 
2 (15.4%) 
34 (45.3%) 
6 (21.4%) 
 
31 (31.6%) 
49 (32.2%) 
2 (100%) 
7 (53.8%) 
31 (41.3%) 
12 (42.9%) 
 
35 (35.7%) 
41 (27.0%) 
0 (0%) 
4 (30.8%) 
10 (13.3%) 
10 (35.7%) 
 
98 
152 
2 
13 
75 
28 
BMI in kg/m2 
Underweight  
Normal weight ( 
Overweight  
Obese  
Missing 
 
2 (40.0%) 
24 (36.9%) 
41 (43.6%) 
59 (36.4%) 
 
1 (20.0%) 
18 (27.7%) 
31 (33.0%) 
66 (40.7%) 
 
2 (40.0%) 
23 (35.4%) 
22 (23.4%) 
37 (22.8%) 
 
5 
65 
94 
162 
42 
Type of diabetes mellitus 
Type 1 
Type 2 
 
2 (8.7%) 
134 (38.8%) 
 
5 (21.7%) 
127 (36.8%) 
 
16 (69.6%) 
84 (24.3%) 
 
23 
345 
Duration of Diabetes in years 
< 5 
5-10 
> 10 
Missing 
 
74 (42.5%) 
25 (29.8%) 
29 (31.2%) 
 
58 (33.3%) 
29 (34.5%) 
37 (39.8%) 
 
42 (24.1%) 
30 (35.7%) 
27 (29.0%) 
 
174 
84 
93 
17 
Duration of attending block 6 
clinic 
<3 years 
≥3 years 
Missing 
 
75 (40.1%) 
60 (33.5%) 
 
55 (29.4%) 
76 (42.5%) 
 
57 (30.5%) 
43 (24.0%) 
 
187 
179 
2 
Modality of treatment of diabetes 
Diet 
Oral hypoglycemic agents (OHAs) 
Insulin 
 
3 (75.0%) 
98 (45.4%) 
11 (21.6%) 
 
1 (25.0%) 
77 (41.6%) 
17 (33.3%) 
 
0 (0%) 
41 (19.0%) 
23 (45.1%) 
 
4 
216 
51 
10 
 
Both OHAs and Insulin 24 (24.7%) 37 (38.1%) 36 (37.1%) 97 
Number of OHAs 
One 
Two 
Missing 
 
58 (36.7%) 
64 (41.3%) 
 
55 (34.8%) 
59 (38.1%) 
 
45 (28.5%) 
32 (20.6%) 
 
158 
155 
55 
Presence of complications 
Yes 
No 
 
108 (35.8%) 
28 (42.4%) 
 
113 (37.4%) 
19 (28.8%) 
 
81 (20.6%) 
19 (28.8%) 
 
302 
66 
Average Blood pressure 
Controlled  (<140/90mmHg) 
Uncontrolled (≥140/90mmHg) 
 
58 (37.4%) 
78 (36.6%) 
 
51 (32.9%) 
81 (38.0%) 
 
46 (29.7%) 
54 (25.4%) 
 
155 
213 
HIV status 
Positive 
Negative 
Don’t know 
 
19 (50.0%) 
76 (33.8%) 
41 (39.0% 
 
8 (21.1%) 
87 (38.7%) 
37 (35.2%) 
 
11 (28.9%) 
62 (27.6%) 
27 (25.5%) 
 
38 
225 
105 
Anaemia 
Moderate 
Mild 
No anaemia 
 
11 (37.9%) 
17 (32.1%) 
104 (38.0%) 
 
8 (27.6%) 
21 (39.6%) 
99 (36.1%) 
 
10 (34.5%) 
15 (28.3%) 
71 (25.9%) 
 
29 
53 
274 
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Table 2: Factors associated with good glycemic control among the study population 
 
Variables Desirable control Suboptimal control 
Crude OR (95% 
CI) 
p-value Crude OR 
(95%CI) 
p-value 
Gender 
Male 
Female 
 
1 (Ref)  
1.913 (1.09-3.36)  
 
 
0.024 
 
1 (Ref) 
1.46 (0.84-2.53) 
 
 
0.177 
Age in years 
21-35 
36-50 
51-65 
≥66 
 
1 (Ref) 
3.23 (1.04-10.06) 
6.27 (2.17-18.16) 
12.24 (3.98-
37.60) 
 
 
0.043 
0.001 
<0.001 
 
1 (Ref) 
4.31 (1.41-
13.15) 
7.24 (2.51-
20.89) 
7.53 (2.40-
23.61) 
 
 
0.01 
<0.001 
0.001 
Highest level of education 
No formal education 
Less than primary school 
Primary school completed 
Secondary school completed 
College/University completed 
Postgraduate degree 
 
1 (Ref) 
0.75 (0.33-1.70) 
0.91 (0.41-2.06) 
0.51 (0.22-1.18) 
0.40 (0.15-1.05) 
2.13 (0.22-20.73) 
 
 
0.493 
0.829 
0.115 
0.062 
0.514 
 
1 (Ref) 
0.76 (0.32-1.80) 
1.46 (0.64-3.32) 
0.78 (0.34-1.82) 
0.57 (0.21-1.49) 
0.70 (0.04-
11.96) 
 
 
0.53 
0.37 
0.57 
0.25 
0.80 
Marital status 
Married/ Cohabiting  
Single/ Separated/Widowed 
 
1 (Ref) 
1.04 (0.62-1.74) 
 
 
0.879 
 
1 (Ref) 
1.21 (0.72-2.04) 
 
 
0.47 
BMI in kg/m2 
Underweight  
Normal weight  
Overweight  
Obese  
 
1 (Ref) 
1.04 (0.14-8.04) 
1.86 (0.25-14.15) 
1.60 (0.22-11.81) 
 
 
0.967 
0.547 
0.648 
 
1 (Ref) 
1.56 (0.13-
18.661) 
2.82 (0.24-
33.05) 
3.57 (0.31-
40.69) 
 
 
0.723 
0.409 
0.306 
Type of diabetesmellitus 
Type 1 
Type 2 
 
1 (Ref) 
12.76 (2.86-
56.91) 
 
 
0.001 
 
1 (Ref) 
4.84 (1.71-
13.71) 
 
 
0.003 
Duration of Diabetes in years 
< 5 
5-10 
> 10 
 
1 (Ref) 
0.47 (0.25-0.91) 
0.61 (0.32-1.16) 
 
 
0.02 
0.13 
 
1 (Ref) 
0.70 (0.37-1.34) 
0.99 (0.53-1.87) 
 
 
0.28 
0.98 
Duration of attending block 6 
clinic 
<3 years 
≥3 years 
 
1 (Ref) 
1.06 (0.63-1.79) 
 
 
0.83 
 
1 (Ref) 
1.83 (1.08-3.10) 
 
 
0.024 
Modality of treatment of 
diabetes 
Diet 
Oral hypoglycemic agents 
(OHAs) 
 
>1000** 
3.59 (1.91-6.75) 
0.72 (0.30-1.74) 
1 (Ref) 
 
 
<0.001 
0.462 
 
>1000** 
1.83 (1.01-3.31) 
0.72 (0.33-1.56) 
 
 
0.047 
0.406 
12 
 
Insulin 
Both OHAs and Insulin 
Number of OHAs 
One 
Two 
 
1 (Ref) 
1.55 (0.87-2.76) 
 
 
0.135 
 
1 (Ref) 
1.51 (0.84-2.70) 
 
 
0.167 
Presence of complications 
Yes 
No 
 
1 (Ref) 
1.11 (0.58-2.12) 
 
 
0.763 
 
1 (Ref) 
2.82 (0.91-8.72) 
 
 
0.349 
Average Blood pressure 
Controlled  (<140/90mmHg) 
Uncontrolled (≥140/90mmHg) 
 
1 (Ref) 
1.15 (0.68-1.93) 
 
 
0.608 
 
1 (Ref) 
1.91 (0.87-4.19) 
 
 
0.261 
HIV status 
Positive 
Negative 
Don’t know 
 
1 (Ref) 
1.41 (0.62-3.18) 
1.24 (0.69-2.24) 
 
 
0.409 
0.477 
 
1 (Ref) 
0.52 (0.20-1.36) 
0.98 (0.56-1.77) 
 
 
0.183 
0.938 
Anaemia 
Moderate 
Mild 
No anaemia 
 
1 (Ref) 
0.75 (0.30-1.86) 
0.77 (0.36-1.65) 
 
 
0.536 
0.507 
 
1 (Ref) 
0.57 (0.22-1.53) 
`1.00 (0.48-2.08) 
 
 
0.266 
0.991 
Poor control category is used as a reference category on the dependent variables 
**The hessian matrix is almost singular 
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Table 3: Multinomial logistic regression of factors associated with glycemic control 
 
Variables Desirable control Suboptimal control 
Adjusted OR  
(95% CI) 
p-value Adjusted OR 
(95%CI) 
p-value 
Gender 
Male 
Female 
 
1 (Ref)  
0.78 (0.33-1.84) 
 
 
0.57 
 
1 (Ref) 
0.67 (0.29-1.55) 
 
 
0.35 
Age in years 
21-35 
36-50 
51-65 
≥66 
 
1 (Ref) 
2.03 (0.30-13.69) 
4.32 (0.63-29.80) 
11.70 (1.40-
97.69) 
 
 
0.463 
0.137 
0.023 
 
1 (Ref) 
10.16 (0.82-1.26) 
13.99 (1.11-177.27) 
16.31 (1.10-241.70) 
 
 
0.07 
0.04 
0.04 
Highest level of education 
No formal education 
Primary to secondary completed 
College/University/Postgraduate 
completed 
 
1 (Ref) 
1.44 (0.44-4.74) 
1.14 (0.42-3.10) 
 
 
0.552 
0.796 
 
1 (Ref) 
1.28 (0.40-4.13) 
1.08 (0.40-2.96) 
 
 
0.68 
0.88 
Marital status 
Married/ Cohabiting  
Single/ Separated/Widowed 
 
1 (Ref) 
1.41 (0.69-2.89) 
 
 
0.35 
 
1 (Ref) 
1.96 (0.97-3.98) 
 
 
0.60 
BMI in kg/m2 
Underweight/Normal (<24.99) 
Overweight/Obese (25-) 
 
1 (Ref) 
1.38 (0.53-3.59) 
 
 
0.51 
 
1 (Ref) 
1.61 (0.61-4.27) 
 
 
0.336 
Duration of Diabetes in years 
< 5 
5-10 
> 10 
 
1 (Ref) 
0.34 (0.13-0.86) 
0.42 (0.15-1.15) 
 
 
0.02 
0.09 
 
1 (Ref) 
0.39 (0.15-0.98) 
0.57 (0.22-1.50) 
 
 
0.04 
0.25 
Duration of attending block 6 
clinic 
<3 years 
≥3 years 
 
1 (Ref) 
1.54 (0.68-3.45) 
 
 
0.30 
 
1 (Ref) 
3.71 (1.66-8.31) 
 
 
0.001 
Modality of treatment of 
diabetes 
Diet/ 
Oral hypoglycemic agents 
(OHAs) 
Insulin/ 
Both OHAs and Insulin 
 
 
6.41 (2.28-18.00) 
 
1 (Ref) 
 
 
<0.001 
 
 
 
2.96 (1.03-8.47) 
 
 
 
0.043 
 
Number of OHAs 
One 
Two 
 
1 (Ref) 
0.47 (0.18-1.20) 
 
 
0.11 
 
1 (Ref) 
0.79 (0.52-1.30) 
 
 
0.638 
Presence of complications 
Yes 
No 
 
1 (Ref) 
0.76 (0.44-1.30) 
 
 
0.70 
 
1 (Ref) 
2.82 (0.91-8.72) 
 
 
0.25 
Average Blood pressure 
Controlled  (<140/90mmHg) 
Uncontrolled (≥140/90mmHg) 
 
1 (Ref) 
1.04 (0.67-1.59) 
 
 
0.11 
 
1 (Ref) 
1.30 (0.59-2.84) 
 
 
0.511 
HIV status 
Positive 
Negative 
 
1 (Ref) 
4.29 (1.00-18.32) 
 
 
0.05 
 
1 (Ref) 
1.08 (0.23-5.09) 
 
 
0.922 
14 
 
Don’t know 1.39 (0.60-3.21) 0.44 1.75 (0.76-4.06) 0.189 
Anaemia 
Moderate 
Mild 
No anaemia 
 
1 (Ref) 
0.56 (0.15-2.14) 
0.85 (0.31-2.37) 
 
 
0.397 
0.762 
 
1 (Ref) 
0.50 (0.13-1.93) 
0.83 (0.30-2.25) 
 
 
0.317 
0.706 
 
 
Table 4: Association between serum creatinine and glycemic control 
 
Variable Desirable 
control 
Suboptimal 
control 
Poor 
control 
p-value 
Mean serum 
creatinine in 
umol/l (SD) 
71.55 
(28.17) 
74.33 
(31.36) 
75.44 
(41.62) 
0.645 
 
